Cantor Fitzgerald Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Key Points

• Cantor Fitzgerald raised Regeneron Pharmaceuticals’ price target from $795 to $980 and maintained an “overweight” rating, implying 5.62% upside from the previous close.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and average price target of $872; individual targets range as high as $1,030.
• Regeneron reported quarterly adjusted EPS of $20.07, beating estimates of $16.51, while revenue rose 36.3% year over year to $5.12 billion. Insiders have sold about $6.5 million of shares over the past 90 days.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price raised by equities research analysts at Cantor Fitzgerald from $795.00 to $980.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective would suggest a potential upside of 5.62% from the company's previous close.

Other research analysts have also issued research reports about the stock. Leerink Partners increased their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research note on Monday, August 17th. The Goldman Sachs Group lifted their target price on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a "buy" rating in a report on Friday, July 31st. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Finally, Raymond James Financial raised their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an "outperform" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $872.00.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $927.89 on Monday. The firm has a market capitalization of $95.54 billion, a price-to-earnings ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $935.35. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06. The stock has a 50 day moving average of $793.30 and a 200 day moving average of $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company's quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $11.83 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Kathryn Guarini sold 400 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company's stock, valued at $512,550. The trade was a 39.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $26,000. Armstrong Advisory Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth $29,000. Trust Co. of Vermont purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. Finally, Fiduciary Financial Advisors acquired a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.